Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes:A systematic review and meta-analyses of animal studies by Ramsteijn, A S et al.
 
 
 University of Groningen
Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes
Ramsteijn, A S; Van de Wijer, L; Rando, J; van Luijk, J; Homberg, J R; Olivier, J D A
Published in:
Neuroscience and Biobehavioral Reviews
DOI:
10.1016/j.neubiorev.2020.04.010
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Ramsteijn, A. S., Van de Wijer, L., Rando, J., van Luijk, J., Homberg, J. R., & Olivier, J. D. A. (2020).
Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes: A systematic review
and meta-analyses of animal studies. Neuroscience and Biobehavioral Reviews, 114, 53-69.
https://doi.org/10.1016/j.neubiorev.2020.04.010
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Contents lists available at ScienceDirect
Neuroscience and Biobehavioral Reviews
journal homepage: www.elsevier.com/locate/neubiorev
Review article
Perinatal selective serotonin reuptake inhibitor exposure and behavioral
outcomes: A systematic review and meta-analyses of animal studies
A.S. Ramsteijna, L. Van de Wijerb, J. Randoc, J. van Luijkd, J.R. Hombergc,*,1, J.D.A. Oliviera,1
a Department of Neurobiology, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands
bDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
c Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands
d SYRCLE, Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands














Reflex and pain sensitivity
Selective serotonin reuptake inhibitors (SSRIs)
Sensory processing





A B S T R A C T
In the Western world, 2–5 % of pregnant women use selective serotonin reuptake inhibitor (SSRI) anti-
depressants. There is no consensus on the potential long-term neurodevelopmental outcomes of early SSRI ex-
posure. Our aim was to determine whether there is an overall effect of perinatal SSRI exposure in animals on a
spectrum of behavioral domains. After a comprehensive database search in PubMed, PsycINFO, and Web of
Science, we included 99 publications. We performed nine meta-analyses and two qualitative syntheses corre-
sponding to different behavioral categories, aggregating data from thousands of animals. We found evidence for
reduced activity and exploration behavior (standardized mean difference (SMD) −0.28 [−0.38, −0.18]), more
passive stress coping (SMD −0.37 [−0.52, −0.23]), and less efficient sensory processing (SMD −0.37 [−0.69,
−0.06]) in SSRI- versus vehicle-exposed animals. No differences were found for anxiety (p = 0.06), social
behavior, learning and memory, ingestive- and reward behavior, motoric behavior, or reflex and pain sensitivity.
Exposure in the period equivalent to the human third trimester was associated with the strongest effects.
1. Introduction
Depression during pregnancy is common, and carries risks for both
mother and child . Antidepressant medication is prescribed for mod-
erate and severe perinatal depression (Vigod et al., 2016). The most
popular antidepressants are selective serotonin reuptake inhibitors
(SSRIs), and their use during pregnancy has increased tremendously
over the past decades (Bakker et al., 2008; Jimenez-Solem et al., 2013;
Cooper et al., 2007; Andrade et al., 2008). Recent estimates of SSRI
exposure in large population-based studies range from 2.5 to 3.3 % of
pregnancies in Europe (Zoega et al., 2015; Jordan et al., 2016) to
2.7–5.4 % in the US (Hayes et al., 2012; Huybrechts et al., 2015). These
numbers imply that every year, in these regions alone, hundreds of
thousands of newborns have been exposed to SSRIs. Although major
teratogenic effects are absent, in utero SSRI exposure has been asso-
ciated with increased risk of neonatal complications such as premature
birth (Alwan et al., 2016). SSRIs reach the developing fetus by crossing
the placental barrier (Rampono et al., 2009). During fetal development,
the serotonin transporter (SERT), the target of SSRIs, is much more
diffusely expressed in the brain than during adulthood (Gaspar et al.,
2003). In fact, the entire serotonergic neurotransmitter system func-
tions differently in adulthood than during development. In adulthood,
serotonin is involved in fundamental brain functions such as the reg-
ulation of mood, sleep and wake rhythms, aggression, appetite, learning
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and memory, and reward (Muller and Jacobs, 2009), while during early
development, serotonin serves as a neurotrophic factor mediating basic
processes such as neurogenesis, cell migration, axon guidance, den-
dritogenesis and synaptogenesis (Teissier et al., 2017). Consequently,
by reaching the brain and modulating serotonin regulation at crucial
neurodevelopmental stages, SSRIs could interfere with brain circuit
formation and lifelong mental health (Brummelte et al., 2017).
This is the rationale for the “SSRI paradox”: the phenomenon in
which adult SSRI exposure decreases symptoms of anxiety and de-
pression, while in utero SSRI exposure increases the risk of developing
anxiety and depression (Homberg et al., 2010). There is mixed evidence
for this theory from human studies, which do not always identify long-
lasting neurodevelopmental effects of perinatal SSRI exposure. On the
one hand, studies have reported higher levels of anxiety (Hanley et al.,
2015) and lower scores on motor-, social-emotional- and adaptive be-
havioral tests (Hanley et al., 2013) after prenatal SSRI exposure. On the
other hand, other studies found no association between in utero SSRI
exposure and intellectual disability (Viktorin et al., 2017), executive
functioning (Hutchison et al., 2019), and emotional or social problems
(Lupattelli et al., 2018). Most of the evidence is obtained from studies in
infants and children, likely due to the practical challenges of examining
the effects of in utero exposure to SSRIs on behavioral outcomes in
adulthood (Oberlander et al., 2009). Interestingly, some of the reported
associations are modulated by behavioral outcome domain (Johnson
et al., 2016; Brown et al., 2016), timing of exposure (Lupattelli et al.,
2018), and sex (Brown et al., 2016; Smearman et al., 2019). Summar-
izing the available evidence, a recent meta-analysis reported significant
positive associations between SSRI exposure during pregnancy and the
development of mental and behavioral disorders such as autism spec-
trum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD),
and mental disability (Halvorsen et al., 2019). However, a number of
other studies found no significant relationship between SSRI exposure
and ASD (Sujan et al., 2017; Brown et al., 2017) and ADHD (Sujan
et al., 2017) after correcting for possible confounding factors. This
suggests that genetic and shared environmental factors, rather than
SSRI exposure, are responsible for the reported associations
(Oberlander and Zwaigenbaum, 2017). Indeed, it is known that ma-
ternal mental health issues during pregnancy are linked to long-term
neurodevelopmental outcomes in children (Gentile, 2017). Since asso-
ciations with SSRI exposure may be confounded by factors such as the
severity of mental health problems, it remains difficult to draw con-
clusions on causality (Halvorsen et al., 2019).
In contrast to human studies, experimental studies in laboratory
animals allow for investigation of the causal relationship between
perinatal SSRI exposure and long-term neurodevelopmental outcomes
(Zucker, 2017). From human studies, in which SSRI exposure only oc-
curs in depressed mothers, it is not clear whether any effects of SSRI
exposure are due to direct effects of the drug on the developing fetus, or
indirect effects on the mother’s mental health status, or a combination
of both. In animals, we have the ability to study the developmental
effects of SSRI treatment during a healthy pregnancy to obtain insight
in the developmental effects of SSRIs per se, although it should be noted
that treatment in the context of maternal stress bears more translational
value. Our knowledge on how serotonergic alterations during devel-
opment affect behavioral outcomes is still limited, and animals provide
great value in unraveling mechanisms underlying such alterations.
Animal experiments have several advantages over human research,
such as a high degree of control over drug dosing and period of ex-
posure. Laboratory rodents mature much faster than humans, yet the
sequence of brain developmental milestones is remarkably similar
(Semple et al., 2013). In addition, placental transfer of SSRIs is similar
between humans and mice (Noorlander et al., 2008) and rats (Olivier
et al., 2011). The last decade especially has witnessed a major surge in
animal studies examining various neurobiological outcomes of peri-
natal SSRI exposure, which have been described in numerous narrative
reviews (Brummelte et al., 2017; Gingrich et al., 2017; Glover and
Clinton, 2016; Grieb and Ragan, 2019; Bourke et al., 2014; Millard
et al., 2017; Ornoy, 2017). To maximize the translational value of an-
imal studies, and in line with efforts to reduce the use of animals in
research, it is imperative to comprehensively bundle all available pre-
clinical evidence. Our aim is to systematically review and analyze
preclinical studies in order to determine whether there is an overall
effect of perinatal SSRI exposure on later-life behavior in animal
models, and if so, under what conditions. We focus particularly on
potential sex differences, interactions with stress exposure, and the
timing of SSRI exposure. The results of this review and accompanying
meta-analyses may assist in understanding the mixed results of peri-
natal SSRI exposure in human studies and inform future study design.
2. Methods
The review protocol was registered at the SYRCLE website (www.
syrcle.nl) in 2016. The reporting in this systematic review adheres to
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (Moher et al., 2009).
2.1. Search strategy
Three databases were searched systematically from inception to
February 27th 2018: PubMed, PsycINFO, and Web of Science. The in-
itial search was performed by JR on April 19th 2016. An updated search
was performed by AR on February 27th 2018. We searched for the
following concepts, using both controlled terms (i.e. MeSH) and free
text words: (i) perinatal exposure; (ii) selective serotonin reuptake in-
hibitor (SSRI); (iii) animal (Supplementary File 1). The SYRCLE animal
filter (Hooijmans et al., 2010) was used for PubMed and adapted for
PsycINFO and Web of Science. The bibliographic records retrieved were
imported and de-duplicated in Mendeley.
2.2. Eligibility screening
Studies were eligible for inclusion if they compared behavioral
outcomes of animals perinatally exposed to SSRIs to those of animals
exposed to a vehicle treatment. Two reviewers independently screened
all identified records for eligibility in two stages using EROS 3.0 (Early
Review Organizing Software, Institute of Clinical Effectiveness and
Health Policy, Buenos Aires, Argentina). JR and LW performed the
screening for the articles identified in the initial search, and AR and LW
for those identified in the updated search. Disagreements were resolved
by discussion.
The first screening stage involved screening only the title and ab-
stract of the articles. Articles were excluded for one or more of the
following reasons: (i) not an original primary study (e.g. review, edi-
torial, conference abstract without full data available) or correction to
an original primary study; (ii) not an in vivo mammalian (non-human)
study; (iii) no SSRI treatment.
In the second stage, the full text of all articles passing the first stage
was consulted. Articles were excluded at this stage for one or more of
the following reasons: (i) not an original primary study (e.g., review,
editorial, conference abstract without full data available or data pub-
lished in duplicate) or correction to an original primary study; (ii) not
an in vivo mammalian (non-human) study; (iii) no SSRI treatment; (iv)
no exposure on or before the developmental day equivalent to human
birth in terms of neurogenesis, GABA cortex development, and axon
extension, calculated using the Translating Time tool developed by
Workman et al. (2013): PND11 in mice and PND10 in rats; (v) no be-
havior analyses; (vi) no control population; (vii) animals subjected to
other factors (e.g., genetic mutation, repeated exposure to additional
drug), but studies in which animals or their mothers were exposed to
stress were included because these studies are translationally relevant;
(viii) no repeated exposure; (ix) no English full text or translation
available.
A.S. Ramsteijn, et al. Neuroscience and Biobehavioral Reviews 114 (2020) 53–69
54
2.3. Extraction of study characteristics and data
The following study characteristics were extracted: (i) study ID:
authors, year, title; (ii) study design characteristics: no. of groups, no. of
animals per group, no. of litters per group, litter size, repeated measures
vs. comparison between groups; (iii) animal model characteristics:
species, strain, sex, age at testing, presence/absence of stress exposure;
(iv) intervention characteristics: type of control, type of SSRI, age and
duration of exposure, administration method, dosage (concentration,
volume of administration); (v) outcome measures: behavioral test used,
test outcome; (vi) other: no. of animals excluded from statistical ana-
lysis, reason for excluding animals.
Then, the data from all behavioral outcomes were extracted: means,
standard deviation (SD) or standard error of the mean (SEM) and
number of animals (N). The methods for extraction were, in order of
priority, (i) extract data from text or tables; (ii) extract data from figures
using digital image analysis software (ImageJ v. 1.52a (Schneider et al.,
2012)); (iii) contact authors for missing data. When SDs/SEMs were not
clearly distinguishable in a figure, we extracted the most conservative
estimate. JR performed the data extraction for all eligible articles re-
trieved in the initial search, and AR for those in the updated search. LW
checked the extraction process for all studies.
2.4. Data analysis
2.4.1. Categorization of behavioral tests
After the data extraction, all behavioral tests found were categor-
ized by AR in consultation with JH and JO and other members of the
Behavioral Neuroscience group at the University of Groningen. Ten
categories were defined – in order of number of comparisons: (i) ac-
tivity & exploration; (ii) anxiety; (iii) stress coping; (iv) social behavior;
(v) learning & memory; (vi) ingestive & reward; (vii) motoric; (viii)
sensory processing; (ix) reflex & pain sensitivity; (x) sleep & circadian
activity. Every category had a number of behavioral tests associated
with it (Supplementary File 2). For every behavioral category we per-
formed a meta-analysis. An exception was the category sleep & circa-
dian activity, which was deemed too heterogeneous and more suitable
for a qualitative synthesis. There was an eleventh category of beha-
vioral tests, in which the animals were challenged with an acute in-
jection of a drug or LPS right before the test. To ensure the analyses for
the above-mentioned behavioral categories were not confounded by the
effects of an acute injection, we decided not to include these results in
any of the 10 categories, and to create a separate qualitative synthesis
for them.
2.4.2. Selection of comparisons
If a study reported separate comparisons for males and females, or
animals exposed to different SSRIs, we analyzed these comparisons as if
they were separate studies. Per meta-analysis, one unique animal can
only be used once. If the same animal was exposed to different beha-
vioral tests within the same category, we used the data from the test
that was performed first (but when data was available from both during
and after SSRI exposure, we used the data from the test performed after
SSRI exposure). If the same animal was exposed to the same behavioral
tests multiple times, we also used the data from the first time it was
administered, unless the test contained an important learning or habi-
tuation component. For that reason, the data from the last time of test
administration was used for the following behavioral tests: alcohol
consumption, cocaine conditioning, forced swim test, Morris water
maze, sexual behavior, sucrose preference test, and tube runway. In the
prepulse inhibition test, usually a range of pulse intensities was tested,
in which case we used the data from the middle intensity. For every
behavioral test, we only used one outcome measure according to the
priority outcome measures we defined (Supplemental File 2). We did
not include non-treated or non-handled controls; only vehicle-treated
controls.
2.4.3. Meta-analyses
We performed the meta-analyses using Review Manager (RevMan
v.5.3., The Nordic Cochrane Centre, The Cochrane Collaboration,
Copenhagen 2014). When a range was reported for N, instead of a
specific number per treatment group (for instance N = 11–13), we used
the most conservative estimate of N. In practice, this meant we used the
maximum value of N (in this case Nmax = 13) to calculate the SD (SD =
SEM*√N), and the minimum value of N (in this case Nmin = 11) in the
actual meta-analysis. We used random effects models using standar-
dized mean differences (SMDs). The individual SMDs were pooled to
obtain an overall SMD and 95 % confidence interval (CI). I2 was used as
a measure of heterogeneity. A p-value lower than 0.05 was considered
significant.
To examine potential sources of heterogeneity within the data, we
performed subgroup analyses using a Chi2 test for subgroup differences
based on sex, presence/absence of stress exposure, and period of SSRI
exposure for every meta-analysis. For the subgroup analysis for sex
there were three subgroups (male, mixed-sex, and female), for pre-
sence/absence of stress exposure there were two (no stress and stress)
and for period of SSRI exposure three (prenatal, pre- and postnatal, and
postnatal). A subgroup analysis was only performed when there was at
least one independent comparison. Although there were six subgroup
analyses defined in the initial published protocol, we decided to only
perform three in order to constrain the scope of this review. We decided
not to perform subgroup analyses based on animal species, timing of
behavioral test, type of SSRI, and specific behavioral test used. Of the
three subgroup analyses we performed, two were included in the ori-
ginal protocol (sex and presence/absence of stress exposure) and one
was added (period of SSRI exposure).
2.5. Risk of bias assessment
The risk of bias is important to evaluate, since the presence of
randomization, allocation concealment, and blinding affects the re-
ported effect sizes of animal studies, in particular in the case of sub-
jective outcome measures (Hirst et al., 2014). To assess the methodo-
logical quality of each included study, we used the SYRCLE risk of bias
tool for animal studies (Hooijmans et al., 2014). We added three
questions on reporting of randomization, blinding, and a power- or
sample size calculation (question 1–3). For these questions, a “Yes”
score indicates that it was reported, and a “No” score indicates that it
was not reported. The other questions (question 4–14) addressed risk of
bias, where “Yes” indicates low risk of bias, “?” indicates unclear risk of
bias, and “No” indicates high risk of bias.
2.6. Publication bias assessment
To assess publication bias, funnel plots were produced for each of
the nine meta-analyses using the package “metafor” v2.1-0
(Viechtbauer, 2010) in R v3.5. Each funnel plot displays all studies in
one plot with SMD as the x-value and 1/√N as the y-value. We used this
method because it was shown that plotting the SMD against the SE can
lead to false-positive results, especially when the included studies have
small sample sizes (Zwetsloot et al., 2017). In the funnel plot, larger
studies with high precision and power will be displayed towards the top
of the graph, around the average SMD. In the absence of publication
bias, smaller studies with lower precision and power will spread evenly
on both sides of the average near the bottom of the graph. If the plot is
asymmetrical, for example when smaller studies predominantly have
SMDs larger than the average, this is an indication of small-study bias,
potentially related to publication bias. To test and adjust for funnel plot
asymmetry, we used the trim and fill method (Duval and Tweedie,
2000) in the “metafor” package.




Through database searching, 5951 records were retrieved, leaving
3930 records after removal of duplicates (Fig. 1). After screening by
title and abstract, 1460 full-text articles were assessed for eligibility,
from which 103 were deemed eligible. After adding one extra article
identified by scanning of the reference lists of the included articles, and
excluding five publications because they did not contain usable data,
we finally included 99 publications in this synthesis of evidence
(Fig. 1).
3.2. Study characteristics
From the 99 included publications, 63 studied rats, 35 mice and one
guinea pigs (Table 1). The majority of studies treated animals with
fluoxetine (67 studies), followed by citalopram (15 studies), zimelidine
(eight studies), escitalopram (five studies), sertraline (four studies),
fluvoxamine (three studies), paroxetine (three studies), and LU 10-134-
C (one study) (Fig. 2A). SSRI exposure was prenatal in 18 studies, both
prenatal and postnatal in 23 studies, and postnatal in 59 studies. From
the studies where SSRIs were administered postnatally (either ex-
clusively, or also prenatally), 54 reported injecting the drug directly
into the pups, and 28 reported exposure through the mother. The
method of SSRI administration was subcutaneous in 43 studies, oral in
31 studies, and intraperitoneal in 25 studies. Forty-seven studies tested
male rats, seven studies female, and 45 studies examined both sexes
(Fig. 2B). Please note that study numbers might add up to more than 99,
because the same study could use multiple SSRIs or exposure periods
(Table 1).
Twenty studies used ways to mimic symptoms associated with
maternal depression in laboratory animals (Table 2). In 19 studies, the
dam was exposed to some form of stress, and in one study the pups were
stressed by means of maternal separation. The most common way to
apply stress to the mother was using repeated restraint stress (10 stu-
dies), followed by chronic unpredictable mild stress (seven studies), and
injections of corticosterone or dexamethasone (one study each).
3.3. Study quality
Forty-eight studies mentioned the experiment was randomized at
some level, 31 reported blinding, and three included a power or sample
size calculation (Supplementary File 3). Overall risk of bias was un-
clear. Only 68 studies reported all outcome measures that were de-
scribed in the methods section.
3.4. Activity and exploration
The meta-analysis for activity and exploration comprised 52 studies
and 134 comparisons (Supplementary File 4). The most used behavioral
test in this category was the open field test with outcome measures such
as total distance moved (121 comparisons), followed by the novel ob-
ject exploration test (six comparisons), running wheel activity (three
comparisons), elevated plus maze (two comparisons), home cage ac-
tivity (one comparison), and object-directed behavior/novel object re-
cognition test (one comparison). In total, 2646 SSRI-exposed animals
and 1627 vehicle-treated animals were included in this analysis.
Overall pooled analysis revealed significantly lower activity scores
in animals that were developmentally exposed to SSRIs than in those
exposed to vehicle (Fig. 3A; Supplementary Fig. 1A, SMD −0.28
[−0.38, −0.18], p<0.00001). Subgroup analysis showed that the
effect was different depending on sex (Fig. 3A; Supplementary Fig. 1B,
Chi² = 13.89, p<0.01). More specifically, while activity scores were
Fig. 1. Study flowchart.
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significantly lower for males (SMD −0.28 [−0.41, −0.15],
p<0.0001) and mixed-sex groups (SMD −0.62 [−0.82, −0.42],
p<0.00001) developmentally exposed to SSRIs versus those exposed to
vehicle, they were not for females (SMD −0.12 [−0.29, 0.04], p =
0.14) (Fig. 3A; Supplementary Fig. 1B). Subgroup analysis based on
stress exposure did not reveal significantly different effects of devel-
opmental SSRI exposure depending on stress exposure (Fig. 3A; Sup-
plementary Fig. 1C, Chi² = 1.76, p = 0.18). Subgroup analysis based
on the period of SSRI exposure showed that the effect of developmental
SSRI exposure on later-life activity and exploration was different de-
pending on exposure timing (Fig. 3A; Supplementary Fig. 1D, Chi² =
11.60, p<0.01). More specifically, while activity scores were not dif-
ferent for those exposed only prenatally (SMD −0.01 [−0.21, 0.19], p
= 0.93), they were significantly lower for animals exposed pre- and
postnatally (SMD−0.40 [−0.59,−0.22], p<0.0001), and postnatally
(SMD −0.39 [−0.51, −0.27], p<0.00001) versus those exposed to
vehicle (Fig. 3A; Supplementary Fig. 1D).
The heterogeneity (I2) of the overall analysis was 49 %. Subgroup
analyses based on sex decreased the heterogeneity to 44 % for males, 39
% for mixed-sex, and 46 % for females. The subgroups based on stress
exposure and SSRI exposure timing did not lower the heterogeneity.
3.5. Anxiety
The meta-analysis for anxiety comprised 55 studies and 133 com-
parisons (Supplementary File 4). The most used behavioral test in this
category was the open field test with outcome measures such as time
spent in center (55 comparisons), followed by the elevated plus maze
(46 comparisons), the novelty-suppressed feeding test (11 compar-
isons), fear during tone (nine comparisons), the defensive withdrawal
test (six comparisons), the elevated zero maze (four comparisons), and
the light-dark test (two comparisons). In total, 1816 SSRI-exposed an-
imals and 1522 vehicle-treated animals were included in this analysis.
Overall pooled analysis did not show significantly different anxiety
scores in animals that were developmentally exposed to SSRIs than in
those exposed to vehicle (Fig. 3B; Supplementary Fig. 2A, SMD 0.10
[−0.00, 0.21], p = 0.06). Subgroup analyses did not reveal sig-
nificantly different effects of developmental SSRI exposure depending
on sex (Fig. 3B; Supplementary Fig. 2B, Chi² = 4.44, p = 0.11), stress
exposure (Fig. 3B; Supplementary Fig. 2C, Chi² = 2.73, p = 0.10), or
period of SSRI exposure (Fig. 3B; Supplementary Fig. 2D, Chi² = 4.95, p
= 0.08).
The heterogeneity (I2) of the overall analysis was 51 %. The sub-
groups based on sex, stress exposure and SSRI exposure timing did not
lower the heterogeneity.
3.6. Stress coping
The meta-analysis for stress coping comprised 30 studies and 90
comparisons (Supplementary File 4). The most used behavioral test in
this category was the forced swim test (55 comparisons), followed by
shock avoidance (30 comparisons), the open field test after stress and
the tail suspension test (two comparisons each), and the elevated plus
maze after stress (one comparison). In total, 955 SSRI-exposed animals
and 806 vehicle-treated animals were included in this analysis.
Overall pooled analysis showed a significantly more passive coping
style in animals that were developmentally exposed to SSRIs than in
those exposed to vehicle (Fig. 3C; Supplementary Fig. 3A, SMD −0.37
[−0.52, −0.23], p<0.00001). Subgroup analyses did not reveal sig-
nificantly different effects of developmental SSRI exposure depending
on sex (Fig. 3C; Supplementary Fig. 3B, Chi² = 1.61, p = 0.45), stress
exposure (Fig. 3C; Supplementary Fig. 3C, Chi² = 1.32, p = 0.25), or
period of SSRI exposure (Fig. 3C; Supplementary Fig. 3D, Chi² = 2.72, p
= 0.26).
The heterogeneity (I2) of the overall analysis was 48 %. The sub-


















































































































































































































































































The meta-analysis for social behavior comprised 30 studies with 53
comparisons (Supplementary File 4). The most used behavioral tests in
this category were sexual behavior and social play behavior (14 com-
parisons each), followed by the social interaction test (10 comparisons),
the social preference test (five comparisons), the resident-intruder test
(four comparisons), ultrasonic vocalizations (three comparisons), ag-
gressive behavior (two comparisons) and maternal behavior (one
comparison). In total, 749 SSRI-exposed animals and 645 vehicle-
treated animals were included in this analysis.
Overall pooled analysis did not show significantly different social
behavior in animals that were developmentally exposed to SSRIs than
in those exposed to vehicle (Fig. 3D; Supplementary Fig. 4A, SMD
−0.07 [−0.27, 0.13], p = 0.47). Whereas subgroup analyses did not
show significantly different effects of developmental SSRI exposure
depending on sex (Fig. 3D; Supplementary Fig. 4B, Chi² = 5.12, p =
0.08) and stress exposure (Fig. 3D; Supplementary Fig. 4C, Chi² = 0.41,
p = 0.52), the effect was different depending on period of SSRI ex-
posure (Fig. 3D; Supplementary Fig. 4D, Chi² = 6.20, p<0.05). More
specifically, while SSRI-exposed offspring did not differ in social be-
havior in those exposed prenatally (SMD 0.34 [−0.16, 0.84], p = 0.18)
and pre- and postnatally (SMD 0.03 [−0.29, 0.35], p = 0.85), animals
exposed to SSRIs postnatally were significantly less pro-social than
those exposed to vehicle (SMD −0.32 [−0.58, −0.05], p<0.05)
(Fig. 3D; Supplementary Fig. 4D).
The heterogeneity (I2) of the overall analysis was 65 %. The sub-
groups based on sex, stress exposure and SSRI exposure timing did not
lower the heterogeneity.
3.8. Learning and memory
The meta-analysis for learning and memory comprised 23 studies
with 47 comparisons (Supplementary File 4). The most used behavioral
test in this category was the Morris water maze (18 comparisons),
followed by the passive avoidance test (eight comparisons), novel ob-
ject recognition (seven comparisons), the Cincinnati water maze (five
comparisons), contextual fear conditioning (three comparisons), the
radial water maze (two comparisons) and the Barnes maze, complex
maze, cued fear conditioning and novel scent recognition (one com-
parison each). In total, 982 SSRI-exposed animals and 679 vehicle-
treated animals were included in this analysis.
Fig. 2. Historical perspective of study characteristics. The cumulative number of publications published each year on behavioral outcomes after perinatal SSRI
exposure in animals, with a focus on (A) the type of SSRI administered and (B) the sex studied.
Table 2
Characteristics of studies combining (maternal) stress with SSRI treatment.
Study ID Dam or pup? Control Stressor Duration Frequency Intervention period … SSRI exposure
Ishiwata et al., 2005 dam undisturbed restraint stress 45 min 3 times/day G15-G21 before
Pivina et al., 2011 dam undisturbed restraint stress 20 min daily G15-G18 before
Rayen et al., 2011 dam undisturbed restraint stress 45 min 3 times/day G15-G21 before
Nagano et al., 2012 dam saline (SC) dexamethasone (50 μg/kg SC) N/A daily G16-G21 before
Bourke et al., 2013 dam undisturbed chronic unpredictable mild stress various various G15-G20 during
Freund et al., 2013 pup handled maternal separation (individual
isolation)
4 h daily P2-P9 during
Knaepen et al., 2013 dam undisturbed restraint stress 45 min 3 times/day G14-G20 before
Rayen et al., 2013 dam undisturbed restraint stress 45 min 3 times/day G15-G21 before
Rayen et al., 2014 dam undisturbed restraint stress 45 min 3 times/day G15-G21 before
Ehrlich et al., 2015 dam undisturbed chronic unpredictable mild stress various various G9-G20 during
Boulle et al., 2016a dam undisturbed restraint stress 45 min 3 times/day G15-G21 before
Boulle et al., 2016b dam undisturbed restraint stress 45 min 3 times/day G15-G21 before
Gobinath et al., 2016 dam sesame oil (1 ml/kg SC) corticosterone (40 mg/kg SC) N/A 2 times/day P2-P23 during
Kiryanova et al., 2016 dam undisturbed chronic unpredictable mild stress various daily G4-G18 before + during
Salari et al., 2016 dam undisturbed restraint stress 40 min 3 times/day G5-G19 before + during
Zohar et al., 2016 dam undisturbed chronic unpredictable mild stress various daily G13-G21 during
Avitsur, 2017 dam food and water deprived restraint stress 45 min 3 times/day G14-G18 during
Gemmel et al., 2017 dam undisturbed chronic unpredictable mild stress various 0-2 times/day G1-G21 before + during
Kiryanova et al., 2017a dam undisturbed chronic unpredictable mild stress various daily G7-G18 before + during
Kiryanova et al., 2017b dam undisturbed chronic unpredictable mild stress various daily G4-G18 before + during
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Overall pooled analysis did not show significantly different learning
and memory in animals that were developmentally exposed to SSRIs
than in those exposed to vehicle (Fig. 3E; Supplementary Fig. 5A, SMD
−0.04 [−0.20, 0.11], p = 0.57). Subgroup analyses revealed sig-
nificantly different effects of developmental SSRI exposure depending
on sex (Fig. 3E; Supplementary Fig. 5B, Chi² = 13.54, p<0.01). More
specifically, the mixed-sex subgroup showed a significantly lower score
on learning and memory tests (SMD −0.36 [−0.54, −0.17],
p<0.001), but this was not the case for the groups consisting of only
males (SMD 0.02 [−0.22, 0.26], p = 0.86) or females (SMD 0.26
[−0.05, 0.57], p = 0.10) (Fig. 3E; Supplementary Fig. 5B). There was
no different effect of developmental SSRI exposure on learning and
memory outcomes depending on stress exposure (Fig. 3E; Supplemen-
tary Fig. 5C, Chi² = 0.13, p= 0.72). In contrast, the effect was different
depending on period of SSRI exposure (Fig. 3E; Supplementary Fig. 5D,
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Fig. 3. Summary forest plots from all meta-analyses comparing animals perinatally exposed to SSRIs to those exposed to vehicle. (A) Activity and exploration. (B)
Anxiety. (C) Stress coping. (D) Social behavior. (E) Learning and memory. (F) Ingestive and reward. (G) Motoric behavior. (H) Sensory processing. (I) Reflex and pain
sensitivity.
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offspring did not differ significantly in learning and memory outcomes
in the groups exposed prenatally (SMD 0.23 [−0.01, 0.48], p = 0.06)
and pre- and postnatally (SMD −0.09 [−0.28, 0.09], p = 0.33), ani-
mals exposed to SSRIs postnatally scored significantly lower on learning
and memory tests than those exposed to vehicle (SMD −0.52 [−0.81,
−0.22], p<0.001) (Fig. 3E; Supplementary Fig. 5D).
The heterogeneity (I2) of the overall analysis was 49 %. Subgroup
analyses based on sex lowered the heterogeneity to 43 % for males, 15
% for mixed-sex, and 48 % for females. The subgroups based on stress
exposure did not lower the heterogeneity. Subgroup analyses based on
SSRI exposure timing lowered the heterogeneity to 42 % for those ex-
posed prenatally, 27 % for those exposed pre- and postnatally, and 28 %
for those exposed postnatally.
3.9. Ingestive- and reward behavior
The meta-analysis for ingestive- and reward behavior comprised 14
studies with 24 comparisons (Supplementary File 4). The most used
behavioral test in this category was food consumption (13 compar-
isons), followed by the sucrose preference test (four comparisons), al-
cohol consumption, cocaine place preference, and the tube runway
(two comparisons each), and cocaine self-administration (one com-
parison). In total, SSRI-exposed animals and vehicle-treated animals
were included in this analysis.
Overall pooled analysis did not show significantly different in-
gestive- and reward behavior in animals that were developmentally
exposed to SSRIs than in those exposed to vehicle (Fig. 3F; Supple-
mentary Fig. 6A, SMD 0.27 [-0.07, 0.60], p = 0.12). Subgroup analyses
did not show significantly different effects of developmental SSRI ex-
posure depending on sex (Fig. 3F; Supplementary Fig. 6B, Chi² = 1.98,
p = 0.37), stress exposure (Fig. 3F; Supplementary Fig. 6C, Chi² =
1.65, p = 0.20), or period of SSRI exposure (Fig. 3F; Supplementary
Fig. 6D, Chi² = 1.33, p = 0.52).
The heterogeneity (I2) of the overall analysis was 69 %. The sub-
groups based on sex, stress exposure and SSRI exposure timing did not
lower the heterogeneity.
3.10. Motoric behavior
The meta-analysis for motoric behavior comprised 11 studies with
20 comparisons (Supplementary File 4). The most used behavioral test
in this category was swimming (seven comparisons), followed by beam
traversing and the rotarod test (five comparisons each), the horizontal
ladder test (two comparisons), and walking (one comparison). In total,
483 SSRI-exposed animals and 370 vehicle-treated animals were in-
cluded in this analysis.
Overall pooled analysis did not show significantly different motoric
behavior in animals that were developmentally exposed to SSRIs than
in those exposed to vehicle (Fig. 3G; Supplementary Fig. 7A, SMD
−0.12 [−0.36, 0.12], p = 0.50). Subgroup analyses did not show
significantly different effects of developmental SSRI exposure de-
pending on sex (Fig. 3G; Supplementary Fig. 7B, Chi² = 1.40, p= 0.50)
or period of SSRI exposure (Fig. 3G; Supplementary Fig. 7C, Chi² =
1.24, p = 0.54). Subgroup analysis based on stress exposure could not
be done because there were no studies with stress exposure in this ca-
tegory.
The heterogeneity (I2) of the overall analysis was 49 %. The sub-
groups based on sex and SSRI exposure timing did not lower the het-
erogeneity.
3.11. Sensory processing
The meta-analysis for sensory processing comprised 12 studies with
17 comparisons (Supplementary File 4). The most used behavioral test
in this category was prepulse inhibition (13 comparisons), followed by
auditory temporal rate discrimination (two comparisons), and gap
crossing and olfactory investigation (one comparison each). In total,
317 SSRI-exposed animals and 310 vehicle-treated animals were in-
cluded in this analysis.
Overall pooled analysis showed significantly less efficient sensory
processing in animals that were developmentally exposed to SSRIs than
in those exposed to vehicle (Fig. 3H; Supplementary Fig. 8A, SMD
−0.37 [−0.69, −0.06], p<0.05). Whereas subgroup analyses did not
show significantly different effects of developmental SSRI exposure
depending on sex (Fig. 3H; Supplementary Fig. 8B, Chi² = 1.71, p =
0.42) and stress exposure (Fig. 3H; Supplementary Fig. 8C, Chi² = 0.23,
p = 0.63), the effect was different depending on period of SSRI ex-
posure (Fig. 3H; Supplementary Fig. 8D, Chi² = 11.67, p<0.01). More
specifically, while SSRI-exposed offspring did not differ in sensory
processing in those exposed prenatally (SMD 0.29 [-0.49, 1.07], p =
0.47) and pre- and postnatally (SMD -0.04 [−0.31, 0.23], p = 0.77),
animals exposed to SSRIs postnatally showed significantly less efficient
sensory processing than those exposed to vehicle (SMD −1.04 [−1.59,
−0.48], p<0.001) (Fig. 3H; Supplementary Fig. 8D).
The heterogeneity (I2) of the overall analysis was 68 %. The sub-
groups based on sex and stress exposure did not lower the hetero-
geneity. Subgroup analyses based on SSRI exposure timing lowered the
heterogeneity to 40 % for those exposed prenatally, 21 % for those
exposed pre- and postnatally, and 68 % for those exposed postnatally.
3.12. Reflex and pain sensitivity
The meta-analysis for reflex and pain sensitivity comprised 11 stu-
dies with 16 comparisons (Supplementary File 4). The most used be-
havioral tests in this category were the hot plate test and negative
geotaxis (six comparisons each), followed by mechanical sensitivity and
righting reflex (two comparisons each). In total, 188 SSRI-exposed an-
imals and 200 vehicle-treated animals were included in this analysis.
Overall pooled analysis did not show significantly different reflex
and pain sensitivity in animals that were developmentally exposed to
SSRIs than in those exposed to vehicle (Fig. 3I; Supplementary Fig. 9A,
SMD −0.25 [−0.73, 0.23], p = 0.31). Subgroup analyses did not show
significantly different effects of developmental SSRI exposure de-
pending on sex (Fig. 3I; Supplementary Fig. 9B, Chi² = 1.33, p= 0.51),
stress exposure (Fig. 3I; Supplementary Fig. 9C, Chi² = 0.02, p= 0.88),
or period of SSRI exposure (Fig. 3I; Supplementary Fig. 9D, Chi² =
3.54, p = 0.17).
The heterogeneity (I2) of the overall analysis was 77 %. The sub-
groups based on sex, stress exposure and SSRI exposure timing did not
lower the heterogeneity.
3.13. Publication bias
Publication bias was assessed using funnel plots. Inspection of the
funnel plots supplemented with trim and fill analysis revealed no
asymmetry for activity and exploration (Supplementary Fig. 10A),
stress coping (Supplementary Fig. 10C), social behavior
(Supplementary Fig. 10D), motoric behavior (Supplementary Fig. 10G),
sensory processing (Supplementary Fig. 10H), and reflex and pain
sensitivity (Supplementary Fig. 10I).
Using trim and fill analysis, we found an indication for funnel plot
asymmetry for three behavioral categories. First, for anxiety, studies
with moderate and low precision showing increased anxiety as a result
of perinatal SSRI exposure were underrepresented, resulting in 20 extra
data points and an adjusted estimated effect size SMD 0.26 [0.14, 0.37]
(Supplementary Fig. 10B). Second, for learning and memory behavior,
studies showing worse test scores as a result of perinatal SSRI exposure
were underrepresented, resulting in 10 extra data points and an ad-
justed estimated effect size of SMD −0.21 [−0.40, −0.02]
(Supplementary Fig. 10E). Finally, for ingestive and reward behavior,
studies showing lower scores of ingestive and reward behavior as a
result of perinatal SSRI exposure were underrepresented, resulting in
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eight extra data points and an adjusted estimated effect size of SMD
−0.12 [−0.49, 0.25] (Supplementary Fig. 10F).
For anxiety and learning and memory, the trim and fill analysis
suggested publication bias might be at play and that the effect size we
found might have underestimated the true effect. However, publication
bias is only one possible explanation for funnel plot asymmetry (Sterne
et al., 2011). Considering strong indications that period of drug ex-
posure mediates the relationship between perinatal SSRI exposure and
later-life behavioral outcomes, we further examined this alternative
explanation. Separate funnel plots and subsequent trim and fill analysis
per exposure period produced no extra data points for anxiety (Sup-
plementary Fig. 10B) and few extra data points for learning and
memory (Supplementary Fig. 10E). This suggests that the funnel plot
asymmetry for these categories can largely be explained by subgroup
heterogeneity.
3.14. Sleep & circadian activity
Seven studies examined the effects of perinatal SSRI exposure on
outcome measures related to sleep and circadian activity (Table 3).
3.15. Behavior after challenges
Thirteen studies examined the effects of perinatal SSRI exposure on
behavioral responses to pharmacological- and immune challenges in
adulthood (Table 4).
4. Discussion
Our main aim was to systematically review and analyze animal
studies to determine whether there is an overall effect of perinatal SSRI
exposure on later-life behavior in a spectrum of behavioral domains.
We included 99 publications and performed nine separate meta-ana-
lyses for different behavioral domains. We found evidence for reduced
activity and exploration behavior in SSRI-exposed (N = 2646) relative
to vehicle-treated (N = 1627) animals. In addition, we found evidence
for a more passive stress coping style in SSRI-exposed (N = 955)
compared to vehicle-treated (N = 806) animals. Lastly, we found evi-
dence for less efficient sensory processing in SSRI-exposed (N = 317)
versus vehicle-treated (N = 310) animals. All effect sizes were small to
medium. We found a tendency for increased anxiety (p = 0.06), while
no differences were found in social behavior, learning and memory,
ingestive- and reward behavior, motoric behavior, and reflex and pain
sensitivity as a result of developmental SSRI exposure in animals.
4.1. Modulating role of sex, stress exposure, and timing of SSRI exposure
Our secondary aim was to examine the conditions under which a
potential effect of developmental SSRI exposure on later-life behavior
would manifest itself. We selected three moderators to examine using
subgroup analyses: animal sex, presence of perinatal stress exposure
(reflecting efforts to mimic aspects of a maternal depressed mood in
animal models), and timing of SSRI exposure.
The sex of the animal tested explained part of the heterogeneity in
the data for two behavioral categories. The male- and the mixed-sex
subgroups showed significantly lower scores for activity and explora-
tion in SSRI-exposed offspring relative to vehicle-exposed offspring,
whereas in females there was no significant difference. Interestingly,
most other behavioral categories also showed larger effect sizes in
males than in females, although these were not statistically significant
effects. For learning and memory, we found a significant effect of SSRI
exposure in the mixed-sex subgroup, but not in the male or female
subgroups. These results may be explained by confounding effects of
other moderators such as the timing of SSRI exposure. In general, it is
important to realize that subgroup analyses are observational in nature,
as they are not based on randomized grouping. To enable more reliable
and informative analyses of potential sex effects in the future, re-
searchers should make their data available separately for males and
females in a supplementary file.
We found no evidence for a modulatory role of stress exposure on
the effects of developmental SSRI exposure on behavior. This could be a
reflection of a true absence of an interaction between perinatal stress-
and SSRI exposure. It could also be due to the large heterogeneity and
wide confidence interval in the stress-exposed group, as a result of the
relatively low number of comparisons and the variation in the nature,
timing and intensity of the stress protocols used. A selective meta-
analysis including only those studies reporting on both stress-un-
exposed and stress-exposed offspring would yield more insight into the
effects of stress exposure, but is beyond the scope of the current review.
The specific period the animal was exposed to an SSRI (prenatal,
Table 3
Study outcomes for sleep & circadian activity.
Study ID Measure Summary of outcome
Hilakivi et al., 1987a Sleep-wake behavior measured with a movement sensitive
mattress
Less active sleep and more wakefulness during neonatal SSRI treatment
Hilakivi et al., 1987b Sleep-wake behavior measured with a movement sensitive
mattress
Less active sleep during neonatal SSRI treatment
Hilakivi et al., 1988a Sleep-wake behavior measured with a movement sensitive
mattress
Less active sleep during neonatal SSRI treatment
Frank and Heller,
1997
Sleep architecture using EEG and EMG More non-REM-REM transitionsa. No differences in sleep and wake amount.
Popa et al., 2008 Sleep architecture using EEG and EMG Total REM sleep duration and frequency is highera. No differences in non-REM sleep.
Kiryanova et al., 2013 Running wheel activity during LD, DD (baseline and after short
light pulse), and LL (baseline and after long dark pulse)
Baseline: free-running period in DD was shortera. Otherwise no differences.
Light pulse: larger phase advance by light pulse at CT22a, but not at CT16. No
difference in phase advance after dark pulse.
Kiryanova et al.,
2017a
Running wheel activity during LD, after LD advance, during DD
(baseline and after short light pulse), and LL
No baseline differences. It took longer to re-entrain to the new LD cyclea. Interaction




REM = rapid eye movement.
LD = light/dark cycle.
DD = constant darkness.
LL = constant light.
CT = circadian time.
a In adult animals developmentally exposed to SSRIs versus vehicle.
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postnatal, or both) explained the most heterogeneity in the data out of
the 3 subgroup analyses we performed. Animals exposed to SSRIs
postnatally – this roughly corresponds to the third trimester in humans
(Workman et al., 2013) – showed reductions in activity and explora-
tion, social behavior, learning and memory, and sensory processing
scores, while animals exposed prenatally – roughly corresponding to
the first two trimesters in humans (Workman et al., 2013) – did not.
4.2. Potential mechanisms
The effects of developmental SSRI exposure on later-life behavioral
outcomes are the result of a combination of direct effects on the de-
veloping brain and indirect effects, for example through changes in
placental and maternal homeostasis (Brummelte et al., 2017) and
postnatal maternal care (Pawluski et al., 2019). The serotonin system
consists of 15 different receptors that are key players at crucial neu-
rodevelopmental stages, regulating neurogenesis, apoptosis, axon
branching and dendritogenesis (Gaspar et al., 2003). Many of the stu-
dies included in the synthesis of evidence in the current review, which
have been selected on the presence of behavioral outcomes, also include
outcomes reflecting brain health from the global to the molecular level:
the corticosterone response to stress (Popa et al., 2008; Pivina et al.,
2011; Bourke et al., 2013; Knaepen et al., 2013; Boulle et al., 2016a, b;
Gobinath et al., 2016; Salari et al., 2016; Gemmel et al., 2017), brain
structure and connectivity (Forcelli and Heinrichs, 2008; Lee, 2009;
Simpson et al., 2011; Smit-Rigter et al., 2012; Rayen et al., 2013, 2014;
Zhou et al., 2015), neuronal health (Ishiwata et al., 2005; Rayen et al.,
2011; Zheng et al., 2011; Lee and Lee, 2012; da Silva et al., 2014; Ko
et al., 2014; Rebello et al., 2014; Gobinath et al., 2016; Gemmel et al.,
2017), monoamine concentrations in the brain (Grimm and Frieder,
1987; Hilakivi et al., 1987a; Pinheiro et al., 2019; Hilakivi et al., 1987b;
Ishiwata et al., 2005; Glazova et al., 2014; Yu et al., 2014; Altieri et al.,
2015; Zohar et al., 2016; Gemmel et al., 2017; Nagano et al., 2017),
protein expression in the brain – mainly related to the serotonergic
system and neurogenesis (Maciag et al., 2006a; Forcelli and Heinrichs,
2008; Capello et al., 2011; Kummet et al., 2012; Nagano et al., 2012;
Francis-Oliveira et al., 2013; Kiryanova et al., 2016; Matsumoto et al.,
2016; Pinheiro et al., 2019), gene expression (Karpova et al., 2009;
Soga et al., 2012; Meyer et al., 2018; Bourke et al., 2013; Sarkar et al.,
2014a, b; Ehrlich et al., 2015; Galindo et al., 2015; Boulle et al., 2016a;
Ishikawa and Shiga, 2017; Pinheiro et al., 2019), and epigenetic mod-
ifications (Karpova et al., 2009; Sarkar et al., 2014a; Toffoli et al., 2014;
Boulle et al., 2016b).
Several mechanisms may underlie our current findings. Earlier work
in serotonin transporter (SERT) knockout rodents, which lack the SERT
and thereby mimic SSRI exposure from conception onwards, showed
that 2 main neural networks were changed compared to wildtype ro-
dents: the somatosensory cortex and the corticolimbic circuit (Homberg
et al., 2010). The first network is likely related to the sensory processing
deficits we found in SSRI-exposed animals. Axons extending from the
thalamus to the cortex transiently express SERT during development,
and disruption of serotonin availability cause them to form aberrant
trajectories (Bonnin et al., 2007, 2011) and affect the development of
the somatosensory cortex (Lee, 2009; Xu et al., 2004). The second
network could be responsible for the effects seen on activity and ex-
ploration and stress coping behaviors. In addition, changes in
Table 4
behavioral outcomes after challenges.
Challenge Measure Summary of outcome Study ID
Central depressants
Alcohol Open field test Stronger inhibitory effect on ambulationa Hilakivi et al., 1987a
Baclofen Forced swim test No different responsea Hilakivi et al., 1988b
Diazepam Elevated plus maze No different response in males or femalesa Favaro et al., 2008
Dizocilpine/MK-801 (NMDA antagonist) Open field test No different responsea Sprowles et al., 2016
Open field test No different responsea Sprowles et al., 2017
Progabide (GABA receptor agonist) Forced swim test Reduced enhancing effect on immobility timea Hilakivi et al., 1988b
Propyleneglycol Elevated plus maze No different response in males or femalesa Favaro et al., 2008
Dopamine system
Apomorphine (D2/D3 agonist) Prepulse inhibition No different responsea Vorhees et al., 1994
Stereotyped behavior No different responsea Hilakivi, 1994
Stereotyped behavior Somewhat reduced stereotypy in femalesa Favaro et al., 2008
Quinpirole (D2/D3 agonist) Open field test No different responsea Stewart et al., 1998
Stereotyped behavior No different responsea Stewart et al., 1998
Immune response
Lipopolysaccharide Food consumption Reduced food consumption in the first 24 h in malesa, not females Avitsur et al., 2015
Food consumption No different responsea Avitsur, 2017
Sucrose consumption Reduced inhibitory effect in the first 60ha in males, not females Avitsur et al., 2015
Sucrose consumption Reduced inhibitory effect in femalesa, not in males Avitsur, 2017
Norepinephrine system
Amphetamine Open field test No different responsea Sprowles et al., 2016
Open field test Reduced stimulant effect Sprowles et al., 2017
Diethylpropion (NE-releasing) Open field test Reduced stimulant effect in femalesa, not males Favaro et al., 2008
Stereotyped behavior Reduced stereotypy in femalesa, not in males Favaro et al., 2008
Salbutamol (β2-adrenergic agonist) Forced swim test Reduced enhancing effect on immobility timea at two months of age, increased
enhancing effect at five months of age
Hilakivi et al., 1988b
Serotonin system
8-OH-DPAT (5-HT1A agonist) Forced swim test No different response in males or femalesa Favaro et al., 2008
Open field test No different response in males or femalesa Favaro et al., 2008
Phase shift Smaller phase advancea Kiryanova et al., 2013
Phase shift Smaller phase advancea Kiryanova et al., 2017a
Fluoxetine (SSRI) Food intake Smaller reduction (none) in food intakea Pinheiro et al., 2019
Prepulse inhibition No different response in males or femalesa Vorhees et al., 1994
a In adult animals developmentally exposed to SSRIs versus vehicle.
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neuroendocrine function could play a role in the development of a more
passive stress coping style in SSRI-exposed animals (Bourke et al.,
2014). It is unclear whether the effects of early SSRI exposure on ac-
tivity and exploration behavior and stress coping behavior have over-
lapping brain correlates.
Lastly, we found higher effect sizes in males (relative to females). In
general, male offspring seem more vulnerable to various types of
stressors during pregnancy than female offspring (Hodes and Epperson,
2019). Early SSRI-exposure may affect males and females differently
because of the sex-specific maturation of the serotonin system
(Brummelte et al., 2017). For instance, serotonin levels in early post-
natal life in rodents are different in males and females: male pups show
a peak of serotonin at PND3, while female pups show more stable
serotonin levels with a later peak (Connell et al., 2004). In addition, it
has been known for a long time that serotonin plays a pivotal role in
sexual differentiation through the hypothalamic-pituitary-gonadal axis
(Ladosky and Gaziri, 1970; Jarzab and Döhler, 1984). Recent evidence
suggests that perinatal SSRI exposure may indeed affect sexual differ-
entiation of the brain and behavior (Rayen et al., 2013). This might be
related to the differential susceptibility of males and females to devel-
opmental exposure to SSRIs.
4.3. Clinical implications
The neurodevelopmental pattern of the serotonin system is re-
markably conserved across species (Gingrich et al., 2017; Bourke et al.,
2014; Millard et al., 2017). Therefore, rodent studies of early SSRI
exposure can yield important insights and circumvent some of the
difficulties of studying this phenomenon in humans. Preclinical and
clinical studies on this topic should ideally continuously inform and
supplement each other.
The finding that early SSRI exposure is linked to a passive coping
style in adult animals is an interesting manifestation of the “SSRI
paradox”. Treatment with antidepressants in adulthood generates a
more active coping style in animals (Slattery and Cryan, 2012) and
alleviates symptoms of depression in humans. Conversely, SSRI treat-
ment in the perinatal period leads to a more passive coping style in
animals later in life. The most common behavioral test in this category
is the forced swim test (Porsolt et al., 1977). The basic premise of this
test is that, confronted with an inescapable situation in a cylinder of
water, rodents can either actively try to escape, or go into a state of
passive floating. This passive behavioral response may be analogous to
maladaptive responses to stress as seen in humans with neuropsychia-
tric disorders (Commons et al., 2017). Similarly, disruptions in sensory
processing like those associated with early SSRI exposure in animals are
present in a spectrum of neuropsychiatric diseases in humans (Hornix
et al., 2019). Our results suggest that the increased risk of symptoms of
neuropsychiatric disorders for those prenatally exposed to SSRIs, as
indicated in some studies (Halvorsen et al., 2019), might be mediated
by differences in stress coping, sensory processing and perhaps anxiety
(Halvorsen et al., 2019; Malm et al., 2016).
A major challenge in human studies is to properly control for the
confounding factor of maternal psychiatric condition (Millard et al.,
2017). Statistical methods aim to approximate this, illustrated by the
finding that the association between in utero SSRI exposure and risk of
ASD was not significant when controlled for maternal psychiatric di-
agnosis (Sorensen et al., 2013). However, a clean comparison between
children from SSRI- and vehicle-treated mothers without any psychia-
tric history is not available. Our results suggest that perinatal SSRI
exposure exerts effects on neurodevelopmental outcomes in animal
studies. As maternal psychiatric disorder might interact with SSRI use
to influence offspring outcomes (Brummelte et al., 2017; Bourke et al.,
2014), researchers and clinicians have questioned how clinically re-
levant rodent studies are. To address this, animal models have been
developed aiming to study SSRI exposure in light of maternal (pre)ge-
stational stress (Brummelte et al., 2017). Our current results do not
support the notion of an interaction effect of maternal stress exposure
and perinatal SSRI exposure on behavioral outcomes in offspring, al-
though the number of studies that examine this is still limited. This is
therefore an important question for future experimental studies and
meta-analyses to focus on.
The first few postnatal weeks in rodents are instrumental in the
maturation of both the serotonin system and cortical circuit wiring, and
also show the highest levels of serotonin and its metabolites in the brain
(Gingrich et al., 2017). In terms of brain development, this period is
approximately equivalent to the third trimester of human gestation
(Workman et al., 2013). Our finding that SSRI exposure in the first
postnatal weeks has the largest effect on later-life behavior in animals
therefore implies that SSRI treatment during the last months of preg-
nancy should have the largest effect on human outcomes. Clinical stu-
dies investigating the effect of timing of SSRI exposure are limited and
inconsistent. In line with current results, a recent study found that late-
pregnancy SSRI exposure was associated with greater depressed and
anxious symptoms in children (Lupattelli et al., 2018), whereas a meta-
analysis found that exposure to SSRIs during the first trimester was most
consistently associated with later diagnosis of mental disorders
(Halvorsen et al., 2019). A Scandinavian study found that SSRI use is
lowest in the third trimester (Zoega et al., 2015), making this the most
challenging trimester to study. Our results suggest, however, that the
timing of SSRI exposure should be a key variable of interest in future
human studies.
Any potential effects of SSRI use on child development notwith-
standing, we want to emphasize that perinatal depression is a serious
illness that needs to be treated. SSRI discontinuation during pregnancy
increases the chance of relapse into depression, with potential harmful
consequences for both mother and child (Chisolm and Payne, 2016).
Therefore, decisions about treatment need to be carefully weighed by
the clinician and their patient.
4.4. Limitations and strengths
One of the limitations of this study is that the quality of the pooled
analyses is only as high as the quality of the individual studies that it
consists of, which is hard to determine. Basic characteristics of best
practices in experimental studies, such as blinding and randomization,
were sparsely reported. This is often the case with animal studies (Avey
et al., 2016; Kilkenny et al., 2009). Especially problematic is the high
percentage of studies not reporting all outcome measures that were
described in their respective methods section, potentially introducing
bias. However, inspection and analysis of funnel plots in search of in-
dications for publication bias was mostly reassuring. Funnel plot
asymmetry was largely accounted for by subgroup heterogeneity and
therefore likely not a sign of publication bias. Other limitations stem
from the features of the animal studies we included, which might not
make them optimally suitable for translation to the human situation.
For instance, many studies employed bolus daily injections that might
lead to transient high serum concentrations of the compounds and their
metabolites because of their relatively short half-life in rodents. In
humans, SSRI use leads to more stable concentrations over the course of
the day (Bourke et al., 2014). In addition, dosing and route of admin-
istration varied widely (Millard et al., 2017). SSRI plasma levels and
placental transfer are sparsely measured.
Additional limitations of this study originate from the choices that
we made regarding data analysis. Since this is the first systematic re-
view of its kind, we took a broad and explorative approach. Before
analyzing the data, 11 behavioral categories were created in consulta-
tion with experts. It is certainly possible that some categories are too
broad in order to find subtle effects. Moreover, many behavioral tests in
the studies that we included have a complex temporal design where, for
instance, reflex development or learning is assessed over several days or
sexual behavior over several weeks. For lack of an overall score of
performance in these tests, we opted to include one time-point in our
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analyses, thereby reducing these often elegant study designs to a snap
shot. Comparison between studies is further complicated by the fact
that not all studies report on similar time-points. In addition, besides
the subgroup analyses we performed, there are other mediators that
may be of interest. These analyses were outside the scope of the current
review, but we do think that comparisons between the different SSRIs,
the different dosages, animal species, timing of behavioral testing, and
the specific test used within each category would be interesting for
future studies and meta-analyses. For example, preliminary data ex-
ploration along these lines suggests that it is mainly the elevated plus
maze that does not show a net effect of perinatal SSRI exposure within
the category anxiety. It would be interesting to explore this further.
The strength of this review is that it is the first effort to compre-
hensively summarize and quantitatively analyze all available evidence
on developmental SSRI exposure on behavioral outcomes in animals.
The sheer number of animals included in our analyses – hundreds to
thousands depending on behavioral category – gives us statistical power
that far exceeds the standard in animal studies. Considering the in-
creasing use of SSRIs during pregnancy (Bakker et al., 2008; Jimenez-
Solem et al., 2013; Cooper et al., 2007; Andrade et al., 2008) and the
uncertainties about their long-term effects on the developing neuro-
biology of the child (Rotem-Kohavi and Oberlander, 2017), studies of
this phenomenon are necessary. We think this review could be valuable
to the field, as we were able to concisely summarize the available an-
imal evidence in order to inform design of future preclinical- as well as
clinical studies.
4.5. Recommendations and future perspectives
Animal studies will continue to play an important role in this field
because of their experimental nature and the ability to mechanistically
study the developmental effects of SSRIs. To improve their transpar-
ency, quality, and utility, pre-registration of animal experiments (e.g.,
www.preclinicaltrials.eu) should become common practice (Jansen of
Lorkeers et al., 2014). In addition, reporting of animal studies should be
improved by adherence to guidelines such as the ARRIVE guidelines
(Kilkenny et al., 2010; Muhlhausler et al., 2013). Animal studies should
be expected to adhere to a high standard of reporting for various rea-
sons: substantial public funds are used to support this work, animals are
sacrificed, and the research informs clinical study design, decision
making, and policy. We would like to emphasize that, although those
responsible for making (all) research results available to the scientific
and wider community are the researchers themselves, other people and
organizations such as funding agencies, universities, collaborating
companies, journal editors and peer reviewers should all use their in-
fluence to make this the norm.
As to future animal study design, we encourage recent trends and
requirements to study both males and females (Clayton and Collins,
2014). Females are understudied, and considering that we found in-
dications of sex effects, it is clearly of interest to study both sexes.
Additionally, the potential interactions of SSRI use with features of
maternal depression remain underinvestigated in animals but are of
high translational value. Further mechanistic studies are required to
elucidate the neurobiological underpinnings of behavioral symptoms
affected by early SSRI exposure. In particular, it remains to be under-
stood whether the effects found on activity and exploration behavior
can be traced back to the same neurodevelopmental processes as those
found on stress coping behavior. Shifting perspectives slightly, one
might wonder why early SSRI exposure does not seem to lead to
stronger and more aberrant behavioral alterations than it does, con-
sidering the ubiquitous role of serotonin in the brain. Animal studies
shed light on individual differences in susceptibility and resilience to
the effects of early SSRI exposure, for example using strains of rats
differing in their novelty seeking traits (Glover et al., 2015).
Implications for future clinical study design appear noteworthy as
well: there is a clear need for studies on the effects of early SSRI
exposure on mental health and behavior extending into adulthood
(Rotem-Kohavi and Oberlander, 2017), especially considering that
phenotypic differences may emerge only after adolescence (Glover and
Clinton, 2016). In addition, while examining the risk for developing
mental disorders is important, it could be equally or perhaps more in-
formative to focus on their shared symptoms. Changes in activity and
exploration, stress coping, and sensory processing are relevant to peo-
ple’s quality of life, even if they are not necessarily tied to the diagnosis
of a mental disorder. Although subgroup analyses are observational by
nature, our results suggest a strong effect of the timing of exposure to
SSRIs on their long-term effect, with exposure in the period corre-
sponding to the third trimester in humans conferring the biggest effects.
Future studies in human populations should therefore seek to include
timing of exposure as a key variable of interest, since this knowledge, if
confirmed in humans, bears great interest for clinicians and pregnant
women suffering from depression.
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